Sympathetic overactivity in hypertension: A risk factor for cardiovascular disease

被引:48
|
作者
Palatini P. [1 ]
机构
[1] Dipartimento di Medicina Clinica e Sperimentale, University of Padova, 35128 Padova, via Giustiniani
关键词
Left Ventricular Mass; High Heart Rate; Sympathetic Outflow; Moxonidine; Eprosartan;
D O I
10.1007/s11906-001-0065-z
中图分类号
学科分类号
摘要
Numerous prospective studies have shown that high heart rate is related to the development of hypertension, atherosclerosis, and incidence of cardiovascular events. Experimental studies in monkeys have shown that high heart rate has direct atherogenic effects on the arteries as a result of increased wall stress. However, clustering of several risk factors for coronary artery disease in persons with high heart rate suggests that sympathetic overactivity also accounts for part of the increased cardiovascular morbidity that is observed in persons with tachycardia. Indeed, experimental studies have shown that heightened sympathetic tone can cause obesity, hyperinsulinemia, and insulin resistance, which in the long term can promote the development of atherosclerosis. Through its interaction with plasma insulin, sympathetic overactivity can promote the development of left ventricular hypertrophy. Sympathetic activation can also increase hematocrit and precipitate a procoagulant state. Angiotensin II has an effect both on the central nervous system, enhancing sympathetic outflow, and on the peripheral sympathetic nerves. Among the angiotensin II receptor antagonists, eprosartan showed a particular ability to block presynaptic angiotensin II receptor 1(AT1) receptors at neuro-effector junctions in the sympathetic nervous system, as well as AT1 receptors in blood vessels. This dual action may represent an important advance in treatment of elevated blood pressure. Copyright © 2001 by Current Science Inc.
引用
收藏
页码:S3 / S9
页数:6
相关论文
共 50 条
  • [31] Systolic hypertension as a cardiovascular risk factor
    McInnes, GT
    BLOOD PRESSURE, 2002, 11 (03) : 134 - 143
  • [32] Arterial hypertension as a cardiovascular risk factor
    Viteri Tinoco, Lesly Andrea
    Lascano Torres, Rosa Selena
    Benitez Villacis, Paola Alexandra
    Aucancela Mora, Henry Israel
    Aispur Rivera, Jefferson Abraham
    Paca Lloay, Alexis Santiago
    Jara Zuniga, Manuel Mesias
    Ascencio Jupiter, Dayanara Magdalena
    Tenezaca Guaman, Jesica Dolores
    REVISTA LATINOAMERICANA DE HIPERTENSION, 2022, 17 (06): : 410 - 415
  • [33] PREGNANCY-INDUCED HYPERTENSION - A STATE OF SYMPATHETIC OVERACTIVITY
    SCHOBEL, HF
    FISCHER, F
    LANGENFELD, M
    SCHMIEDER, RE
    CIRCULATION, 1995, 92 (08) : 2009 - 2009
  • [34] Sympathetic overactivity as a cause of hypertension in chronic renal failure
    Augustyniak, RA
    Tuncel, M
    Zhang, WG
    Toto, RD
    Victor, RG
    JOURNAL OF HYPERTENSION, 2002, 20 (01) : 3 - 9
  • [35] The complex interaction between overweight, hypertension, and sympathetic overactivity
    Feldstein, Carlos
    Julius, Stevo
    JOURNAL OF THE AMERICAN SOCIETY OF HYPERTENSION, 2009, 3 (06) : 353 - 365
  • [36] Hypertension as a risk factor for atherosclerosis: Cardiovascular risk assessment
    Poznyak, Anastasia V.
    Sadykhov, Nikolay K.
    Kartuesov, Andrey G.
    Borisov, Evgeny E.
    Melnichenko, Alexandra A.
    Grechko, Andrey V.
    Orekhov, Alexander N.
    FRONTIERS IN CARDIOVASCULAR MEDICINE, 2022, 9
  • [37] Role of the sympathetic nervous system in hypertension and hypertension-related cardiovascular disease
    Seravalle G.
    Mancia G.
    Grassi G.
    High Blood Pressure & Cardiovascular Prevention, 2014, 21 (2) : 89 - 105
  • [38] Hypertension and cardiovascular disease risk in women
    Thadani, U
    MEDICINE AND SCIENCE IN SPORTS AND EXERCISE, 1996, 28 (01): : 7 - 8
  • [39] Managing cardiovascular disease risk in hypertension
    McManus, Richard
    Constanti, Margaret
    Floyd, Christopher N.
    Glover, Mark
    Wierzbicki, Anthony S.
    LANCET, 2020, 395 (10227): : 869 - 870
  • [40] Involvement of sympathetic overactivity in systolic hypertension in nondiabetic hemodialysis patients
    Nishimura, Masato
    Murase, Masaki
    Hashimoto, Tetsuya
    Kobayashi, Hiroyuki
    Yamazaki, Satoru
    Okino, Koji
    Takahashi, Hakuo
    Ono, Toshihiko
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2006, 21 : 236 - 237